Cargando…

Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study

Vilazodone is a selective serotonin reuptake inhibitor and a 5-HT(1A) receptor partial agonist that is approved for treatment of major depressive disorder in adults in the USA and Mexico. The efficacy, safety, and tolerability of vilazodone for generalized anxiety disorder (GAD) were investigated in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gommoll, Carl, Forero, Giovanna, Mathews, Maju, Nunez, Rene, Tang, Xiongwen, Durgam, Suresh, Sambunaris, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593467/ https://www.ncbi.nlm.nih.gov/pubmed/26291335 http://dx.doi.org/10.1097/YIC.0000000000000096

Ejemplares similares

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER
por: Gommoll, Carl, et al.
Publicado: (2015)

Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone
por: Khan, Arif, et al.
Publicado: (2016)

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Mathews, Maju, et al.
Publicado: (2015)

Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials
por: Thase, Michael E., et al.
Publicado: (2017)

Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study
por: Clayton, Anita H., et al.
Publicado: (2017)

Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial
por: Citrome, Leslie, et al.
Publicado: (2015)

Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies
por: Clayton, Anita H, et al.
Publicado: (2016)

Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial
por: Clayton, Anita H., et al.
Publicado: (2015)

Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial
por: Durgam, Suresh, et al.
Publicado: (2018)

Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials
por: Durgam, Suresh, et al.
Publicado: (2016)

A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
por: Sambunaris, Angelo, et al.
Publicado: (2014)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder
por: Durgam, Suresh, et al.
Publicado: (2018)

Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials
por: Sambunaris, Angelo, et al.
Publicado: (2014)

Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials
por: Kornstein, Susan, et al.
Publicado: (2018)

Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression
por: Khan, Arif, et al.
Publicado: (2014)

Clinical Relevance of Vilazodone Treatment in Patients With Major Depressive Disorder: Categorical Improvement in Symptoms
por: Culpepper, Larry, et al.
Publicado: (2014)

Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study
por: Durgam, Suresh, et al.
Publicado: (2017)

A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
por: Gommoll, Carl P., et al.
Publicado: (2014)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2016)

Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2014)

Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials
por: Montgomery, Stuart A., et al.
Publicado: (2014)

A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up
por: Findling, Robert L., et al.
Publicado: (2020)

Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double‐blind, placebo‐controlled study
por: Durgam, Suresh, et al.
Publicado: (2019)

Vilazodone for the Treatment of Depression: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study
por: Wesnes, Keith A., et al.
Publicado: (2017)

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Fava, Maurizio, et al.
Publicado: (2018)

The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study
por: Montgomery, Stuart A., et al.
Publicado: (2014)

OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females
por: Brin, Mitchell F., et al.
Publicado: (2020)

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
por: Earley, Willie, et al.
Publicado: (2017)

Vilazodone-Induced Hyperglycemia: A Case Series
por: Das, Abhipsa, et al.
Publicado: (2020)

A Phase III Prospective Active and Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Major Depressive Disorder
por: Sinha, Shubhadeep, et al.
Publicado: (2021)

Crystal structure of vilazodone hydrochloride methanol monosolvate
por: Hu, Xiu-Rong, et al.
Publicado: (2016)

A Review of Vilazodone, Serotonin, and Major Depressive Disorder
por: Pierz, Kerri A., et al.
Publicado: (2014)

The antidepressant drug vilazodone is an allosteric inhibitor of the serotonin transporter
por: Plenge, Per, et al.
Publicado: (2021)

Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
por: Mago, Rajnish, et al.
Publicado: (2013)

Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
por: Mago, Rajnish, et al.
Publicado: (2013)

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
por: Zhang, Xiao-Fei, et al.
Publicado: (2015)

The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder
por: Sahli, Zeyad T., et al.
Publicado: (2016)

Randomized trial of vilazodone versus sertraline in depression: Concerns and comments
por: Praharaj, Samir Kumar
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_292j1d806n366q6kot57tlh6fu